News stories about vTv Therapeutics (NASDAQ:VTVT) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. vTv Therapeutics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.9542697523909 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

A number of equities research analysts have recently issued reports on VTVT shares. HC Wainwright set a $13.00 price objective on shares of vTv Therapeutics and gave the company a “buy” rating in a research note on Friday, August 4th. Zacks Investment Research raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price objective for the company in a research note on Saturday, September 30th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $12.00 price objective on shares of vTv Therapeutics in a research note on Friday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $14.10.

Shares of vTv Therapeutics (VTVT) traded up $0.02 on Monday, reaching $6.19. 9,637 shares of the company’s stock traded hands, compared to its average volume of 54,291. vTv Therapeutics has a fifty-two week low of $3.57 and a fifty-two week high of $8.09.

In other news, major shareholder Ronald O. Perelman acquired 85,000 shares of vTv Therapeutics stock in a transaction on Friday, August 11th. The shares were purchased at an average price of $4.13 per share, with a total value of $351,050.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Ronald O. Perelman acquired 50,000 shares of vTv Therapeutics stock in a transaction on Tuesday, August 15th. The shares were purchased at an average cost of $4.72 per share, for a total transaction of $236,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 165,000 shares of company stock worth $728,150. Company insiders own 0.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact vTv Therapeutics (VTVT) Share Price” was posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-vtv-therapeutics-vtvt-share-price/1683624.html.

vTv Therapeutics Company Profile

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Insider Buying and Selling by Quarter for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.